Innoviva to Report Second Quarter 2016 Financial Results on July 28 at 5:00 p.m. EDT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the second quarter ended June 30, 2016 after market close on Thursday July 28, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.

To participate in the live call dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers and enter Conference ID: 49092758. A live webcast of the call will be available at INVA 2Q16 webcast or from the investor relations section of the company website at www.inva.com and will be archived for 30 days. A telephone replay of the call will be available through August 4 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering Conference ID: 49092758.

About Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance Biopharma, Inc., including the closed triple combination therapy for COPD. For more information, please visit Innoviva's website at www.inva.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160720005381/en/

Innoviva, Inc.
Eric d’Esparbes, 650-238-9640
Senior Vice President and Chief Financial Officer
[email protected]

Source: Innoviva, Inc.

You May Also Be Interested In

• Brunswick (BC) Reports In-Line Q1 EPS, provides guidance
• CBIZ REPORTS FIRST-QUARTER 2024 RESULTS
• WEX Inc. Reports First Quarter 2024 Financial Results